DNA repair syndromes are heterogeneous disorders caused by pathogenic variants in genes encoding proteins key in DNA replication and/or the cellular response to DNA damage.
INTRODUCTION
Germline pathogenic variants (i.e., mutations) in key components of DNA repair and telomere biology result in a spectrum of heritable disorders usually associated with characteristic physical findings and an elevated risk of specific cancers. In many instances, the DNA repair disorders are diagnosed in childhood, but some, particularly those caused by aberrant telomere biology, may manifest later in life. Dedicated syndrome registries, basic science, and clinical research have provided insights into the treatment and management for individuals with these rare disorders of aberrant DNA repair mechanisms. This manuscript originates from the October 2016 American Association of Cancer Research Childhood Cancer Predisposition Workshop which focused on reviewing pediatric cancer surveillance guidelines for children with hereditary risk of cancer. Limited data exist to define the true incidence of cancer in the DNA repair disorders and almost no evidencebased approaches exist to evaluate cancer surveillance in patients with DNA repair disorders. Since the comprehensive review of all inherited disorders of DNA repair is beyond the scope of this manuscript and has been done elsewhere, we reviewed the primary clinical manifestations and associated malignancies of these disorders and to provide information on family support groups and/or patient registries as a starting point for clinical management and the future development of evidence-based guidelines (Tables 1 and 2).(1-8) All patients and/or their families are encouraged to promptly report to health care professionals any changes in their health, and physicians should have a low index of suspicion for malignancy in patients with DNA repair disorders. In addition to contacting centers of excellence for these rare disorders, clinicians are referred to https://clinicaltrials.gov to help identify ongoing clinical trials for these disorders.
between one and four years of age. Conjunctival telangiectasias, oculomotor apraxia, choreoathetosis, and immunodeficiency are often also present.(1) The progressive neurologic symptoms are thought to be due to aberrant DNA repair and neuronal cell death with most children with A-T wheelchair bound by the teen years. Malignancy is reported to develop in up to 40% of patients with A-T and is typically non-Hodgkin lymphoma and acute lymphoid leukemia. (12) Cancer Screening/Surveillance/Management Protocols Children with A-T are often diagnosed by a variety of different methods including abnormal newborn screening for reduced T-cell receptor excision circle levels. Other laboratory abnormalities that can be detected in children suspected of having A-T include increased alpha-feto protein (AFP) levels, reduced IgA, IgE, and IgG2 levels, poor antibody response to pneumococcal polysaccharide vaccines, abnormal peripheral blood karyotype analysis including presence of a 7;14 translocation (in 5-15% of patients), and cerebellar hypoplasia on MRI.(1) Increased lymphocyte sensitivity to ionizing radiation is also present.
Patients with A-T require multidisciplinary care including referrals to 1) neurology for progressive cerebellar ataxia, ocular apraxia, and choreoathetosis; 2) immunology/ hematopoietic cell transplant (HCT) for management of immunodeficiency; 3) pulmonology for recurrent infections, pulmonary function evaluation, and restrictive lung disease; 4) gastroenterology (GI) for swallow evaluation and nutrition; and 5) oncology for leukemia, lymphoma and solid tumor risks.
Evidence-based standards for cancer screening do not exist for patients with A-T, particularly in childhood. Annual physical exam, complete blood count, complete metabolic profile including lactate dehydrogenase should be considered. As described in another manuscript in this series, considerable debate exists on whether early diagnosis of acute leukemia improves survival (reference -Porter et al, in this issue). It is important for parents and providers to keep in mind that A-T patients are sensitive to ionizing radiation and xrays, and thus their use should be limited accordingly. Treatment regimens of any incident cancer should be adjusted given the increased risk of treatment related toxicity in children with A-T. Providers and patients should coordinate both acute and chronic care with centers focusing on A-T. The A-T Children's project, http://www.atcp.org, has information for families and physicians.
Individuals who are heterozygous for a single pathogenic ATM variant have increased risk of adult onset breast, prostate and pancreatic cancer (13) (14) (15) . This also has implications for cancer screening in affected parents of children with A-T. The adult onset cancer risk in ATM carriers continues to be extensively studied but remains beyond the scope of this manuscript.
belongs to the MRE11/RAD50 double stranded break repair complex. Patients with NBS are characterized by microcephaly, microgenia (small deformed chin), immunodeficiency and "bird like" facies. (16) NBS is estimated to affect one in 100,000 newborns worldwide, but is thought to be more common in Slavic populations of Eastern Europe. (17) Approximately 40% of affected individuals develop malignancies before age 20. T-cell and B-cell lymphomas are the most common NBS-associated malignancies; medulloblastoma, glioma and rhabdomyosarcoma have also been reported. (17) Laboratory evaluation for NBS shows some similar features as described for children with A-T, including reduced CD3 + and CD4 + T cells, IgA deficiency (20% of patients), IgG2 and IgG4 deficiency (with normal serum IgG), increased frequency of CD45RO + T cells and simultaneous decrease in naïve CD45RA + T-cells (rare) and the same structural aberrations of chromosome 7 and 14 in cultured lymphocytes as seen in AT. Response to testing of ionizing radiation sensitivity in lymphocytes will be abnormal and demonstrate increased sensitivity. Germline genetic testing reveals loss of function mutations in NBN with the Slavic founder mutation being the most common. (6, 17) 
Cancer Screening/Surveillance/Management Protocols
Patients with NBS require multidisciplinary care beginning at diagnosis that is tailored to each patient's specific needs. Patients should be evaluated by an immunologist and for management of immunodeficiency, undergo monitoring by a pulmonologist for recurrent infections, be followed by endocrinology and nutrition evaluations for growth deficiency and by oncology for leukemia, lymphoma and solid tumor risks. Annual CBC is indicated or when symptomatic to assess for hematologic disease. Patients with NBS require often intravenous immunoglobulin therapy for immunodeficiency. (18-21) As described for patients with A-T, children with NBS demonstrate increased sensitivity to ionizing radiation and may require tailored treatment regimens for any malignancy that develops. (22) Heterozygous carriers of pathogenic variants in NBN are at risk for adult onset breast, and prostate cancer. (14, 15, 23) 
BLOOM'S SYNDROME Genetic Summary
Bloom's syndrome (BS, MIM 210900) is an AR disorder resulting from bi-allelic pathogenic variants in the BLM gene encoding the BLM DNA helicase, a member of the RECQ family and sometimes referred to as BLM. (24, 25) RECQ helicase enzymes attach and unwind the DNA double helix. BLM maintains genomic stability during the DNA copying process by limiting sister chromatid exchange. Cells from patients with BS with absent BLM activity demonstrate a ten-times higher rate of sister chromatid exchange.
Only a few hundred individuals with BS have been described, and approximately one-third are of Ashkenazi Jewish descent due to a founder allele. (26) (27) (28) The classic BS characteristics include pre-and postnatal growth deficiency, short stature, sun-sensitivity, gastroesophageal reflux, recurrent infections, decreased fertility in males, insulin resistance, and cancer predisposition.(4) Two hundred twelve cancers in 136 patients have been described in the Bloom's Syndrome Registry.(4) Cancers diagnosed during the pediatric period include gastrointestinal, genital and urinary tract carcinoma, lymphoma, acute lymphoblastic leukemia, acute myeloid leukemia, sarcoma, Wilms tumor, medulloblastoma, and retinoblastoma. (29) Multiple cancers occur commonly and with a distribution that is similar to cancer that is seen in the general population, but with an earlier onset.
Cancer Screening/Surveillance/Management Protocols
There is no established cancer screening protocol for patients with BS, and the risk for cancer at multiple sites presents a surveillance challenge. Patients and their families should be aware of the signs and symptoms of leukemia and lymphoma, the most commonly encountered malignancies in BS, and patients should be evaluated promptly when recognized. The second most common cancer type is colorectal cancer, with the earliest occurrence being at age 16 years. (28) . A reasonable approach to screening includes colonoscopy every 1-2 years and guaiac fecal occult blood testing every 6 months, beginning at age 15 years. Breast cancer was diagnosed in 16 women in the BS Registry at a median age of 35.8 years (range 21 -48) . Based on this information, annual breast MRI scans beginning between ages 20 and 25 is a reasonable surveillance strategy. For the remaining cancers, patients and their families should be aware of the common but nonspecific signs of cancer including unintentional weight loss, unexplained fever, fatigue, changes in bowel or bladder habits, and persistent and unexplained pain. When imaging is used for diagnostic evaluation, ultrasonography and MRI scan are preferred over radiographs or CT scans because of the presumed increased risk for cancer from ionizing radiation. The BS registry has information on various aspects of BS patient care (http://weill.cornell.edu/ bsr/) as does the Bloom's Syndrome Association (http:// www.bloomssyndromeassociation.org). Clinicians should consult with experts in BS on the specific areas of clinical management. An international RECQ disorders meeting (RECQ2016) resulted in a recent plan to further develop BS management guidelines.
ROTHMUND-THOMSON SYNDROME Genetic Summary
Rothmund-Thomson syndrome (RTS, MIM 268400) is a rare disorder with only a few hundred patients described in the literature.(30, 31) Type 2 RTS is associated with an increased cancer risk results due to bi-allelic pathogenic variants in the RECQL4 DNA helicase.(8) The RECQL4 protein, like BLM, belongs to the RECQ DNA helicase family. It is a multifunctional protein which participates in several cellular processes, including DNA replication, DNA damage repair, maintenance of telomeres and mitochondrial DNA integrity. (32, 33) A proportion of individuals with a clinical diagnosis of RTS (based on poikiloderma) do not have an identifiable RECQL4 pathogenic variant (referred to as RTS Type 1) and do not appear to have an increased risk of cancer. The gene for RTS type 1 has not been identified.
Patients with RTS have the characteristic skin finding of poikiloderma (hyper and hypopigmentation, atrophy, and telangiectasias) that starts in infancy and persists throughout life. (34) (35) (36) They may also have sparse hair, hyperkeratosis, small stature, skeletal defects including osteoporosis, dental anomalies, and cataracts. (36) (37) (38) RTS patients develop osteosarcoma at an earlier age than the general population (median age 10 years), so any screening could be limited to the first two decades of life. (39) The incidence of OS in patients with no truncating mutations was 0.00 per year (100 person-years of observation), and the incidence of OS in patients with one or two truncating mutations was 0.05 per year (230 person-years of observation) (P = .037 using the two-sided log-rank test (40) . A smaller number of patients have been described with basal cell carcinoma and skin squamous cell carcinoma (SCC). (40, 41) A specific allele of RECQL4 associated with a related disorder (RAPADILINO syndrome) is associated with an increased risk of lymphoma. (42) Hematologic abnormalities such as bone marrow failure, myelodysplastic syndrome (MDS), lymphoma, and leukemia have also been reported. (36, (43) (44) (45) (46) (47) 
Cancer Screening/Surveillance/Management Protocols
Patients with RTS require multidisciplinary care including evaluations by 1) genetics for counseling about cancer risk; 2) dermatology for annual skin exam and skin care; 3) ophthalmology for cataract screening and management; and 4) dentistry for routine care. Patients are cautioned to avoid excessive radiation (UV or IR) exposure, employ sensible sun protection, and monitor skin for lesions. Retinoids may be used to manage hyperkeratosis, and pulsed laser therapy may be used to improve cosmesis of telangiectasias. (48, 49) RTS patients with pathogenic variants in RECQL4 are recommended to have a skeletal survey before the age of 5 years to identify any underlying skeletal abnormalities; they should receive counseling about the risk of osteosarcoma and be aware of signs and symptoms of osteosarcoma. Should these occur, they should seek immediate medical attention. Any new imaging of affected areas (e.g., x-rays) can be compared to the baseline skeletal survey to determine whether further work-up is warranted. The benefit of routine screening for osteosarcoma has not yet been determined. Factors to consider include timing, length, modality (plain radiographs vs. MRI) and cost of screening.
The RTS Foundation, http://www.rtsplace.org/, has patient-centered information.
DYSKERATOSIS CONGENITA Genetic Summary
Dyskeratosis congenita (DC, MIMs: 127550, 30500, 615190, 613987, 613989) is a telomere biology disorder (TBD) characterized by nail dystrophy, lacy skin pigmentation, and oral leukoplakia. (7, 50) DC is caused by pathogenic variants in genes important in stability and maintenance of telomeres, the nucleoprotein complex essential for chromosomal stability. The mode of inheritance depends on the gene and is X-linked for DKC1, autosomal dominant (AD) for TERC or TINF2, AR for CTC1, NHP2, NOP10, PARN, or WRAP53, and either AD or AR for ACD, RTEL1, or TERT. The prevalence of DC in the general population is unknown. Diagnosis is made by the presence of telomeres less than the first percentile for age measured by flow cytometry with fluorescent in situ hybridization to measure telomere length in white blood cells. 
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Cancer Screening/Surveillance/Management Protocols
The guidelines for diagnosis and management of FA can be found at http://fanconi.org/ index.php/publications/guidelines. A complete blood count (CBC) and bone marrow aspirate and biopsy is recommended at diagnosis. The bone marrow evaluation should then be repeated annually. The CBC should be monitored more frequently to allow for proactive monitoring for progressive cytopenias and MDS. From the time of diagnosis, patients with FA should perform monthly oral self-examinations (or with parents assistance); have a biannual dental examination (general inspection exam without X-rays unless specific indication), and annual HNSCC evaluation by an otolaryngologist beginning in early adolescence. An annual gynecologic examination is recommended starting in adolescence and the HPV vaccine should be administered per the AAP vaccination schedule for both boys and girls. Clinical management of patients with FA do not include standard myeloablative dosing, these lower dose regimens are designed to be myeloablative in the setting of FA, alternatively, androgen therapy may be tried for FA patients with bone marrow failure, as well as, cancer-specific therapy with avoidance of DNA damaging agents, and supportive care for other complications. (3) Parents of children with the more common FA subtypes, FANCA, FANCC, and FANCG, do not appear to have an increased cancer risk. However, heterozygous mutations in several of the more rare FA subtype genes: FANCD1/BRCA2, FANCJ/BRIP1/BACH1, FANCN/ PALB2, FANCO/RAD51C, FANCES/BRCA1, and FANCU/XRCC2 are associated with moderate adult onset cancer risks, particularly for breast and ovarian cancer. Thus, parents of children with these FA subtypes may benefit from increased cancer screening and prevention strategies. The use of multi-gene panel testing for individuals at risk for hereditary breast/ ovarian cancer is increasingly identifying adult carriers who also need to be alerted to their cancer risk as well as their risk for FA in their offspring and options for preconception planning and testing of their partner for the same FA gene. (3, 69) .
The FA family support group, Fanconi Anemia Research Fund, www.fanconi.org, has information for patients, clinicians, and researchers. 
XERODERMA PIGMENTOSUM

HETEROZYGOUS CARRIERS OF PATHOGENIC VARIANTS IN DNA REPAIR GENES
The majority of the DNA repair disorders described above are AR syndromes with a few exceptions. Heterozygous carriers of pathogenic variants in DNA repair genes may have an elevated cancer risk, but the data vary by gene and cancer. Parents of children with AR DNA repair disorders should receive genetic counseling and cancer screening in accordance with national guidelines and expert providers. (23, 80) In addition, non-syndromic children may be heterozygous carriers for DNA damage genes, and recent next generation sequencing studies have identified children with cancer harboring pathogenic variants in these genes. (81) (82) (83) At this time it is not clear if these variants are directly connected to the cancer affecting the children in those studies. Providers should tailor their discussions with these families based on comprehensive patient-specific information including: other clinical features of the disorder being present and other biomarker or functional evidence before determining whether testing and/or screening should be considered for unaffected siblings under the age. It should be noted, however, that genetic testing of children for adult onset diseases is generally not recommended. (84) CONCLUSIONS DNA repair syndromes manifest from heritable underpinnings and when identified, affected individuals require multidisciplinary care, nuanced therapeutic considerations, and screening ( Table 2) . Although these syndromes are rare, dedicated syndrome registries, basic science research, and clinical research continue to develop the foundation for the most appropriate treatment and management for individuals with inherent aberrant DNA repair mechanisms. Centralized centers of excellence are highly recommended to be involved directly or through consultation in caring for patients with heritable pediatric DNA damage syndromes. For parents carrying a single mutation in a DNA damage syndrome gene, screening and prevention considerations may be indicated and necessitate genetic counseling and guidance.
